rtemisinin is an extract from the Chinese plant quinghao (Artemisia annua L) and is used in traditional Chinese medicine for patients with chills and fever. 1 Since 1972, when its antimalarial properties were discovered, artemisinin and its semisynthetic derivatives (ie, arteether, artemether, artesunate, artelinate, and artenimol [dihydroartemisinin]) have been studied extensively as antimalarial agents.
A
rtemisinin is an extract from the Chinese plant quinghao (Artemisia annua L) and is used in traditional Chinese medicine for patients with chills and fever. 1 Since 1972, when its antimalarial properties were discovered, artemisinin and its semisynthetic derivatives (ie, arteether, artemether, artesunate, artelinate, and artenimol [dihydroartemisinin] ) have been studied extensively as antimalarial agents. 2 These compounds react with intracellular iron in free heme molecules within malaria-infected RBCs and are converted to highly reactive free radicals. Their antimalarial activity is attributable to generation of ROS, which are believed to alkylate 1 or more essential malarial proteins. 3, 4 Artemisinins have antineoplastic properties. [5] [6] [7] [8] [9] [10] Similar to the antimalarial effects, the tumoricidal mechanism of artemisinin is secondary to generation of ROS. Because iron is a cofactor in the synthesis of Biological activity of dihydroartemisinin in canine osteosarcoma cell lines deoxyriboses, most neoplastic cells overexpress cell surface transferrin receptors and have greater intracellular iron concentrations than normal somatic cells.
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This may explain the basis of the selective cytotoxic effects of artemisinins for neoplastic cells. For example, human leukemia and breast cancer cells are up to 100-fold more sensitive to the cytotoxic effects of arteminisin than are normal human lymphocytes and breast epithelial cells. 8, 12 Several additional studies [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] have revealed that artemisinin and its derivatives have cytotoxic effects against multiple human cell lines in vitro and against a rat fibrosarcoma cell line in vivo. Finally, the potential clinical efficacy of artemisinin derivatives has been indicated in case reports [22] [23] [24] of humans with laryngeal squamous cell carcinoma, metastatic uveal melanoma, and pituitary macroadenoma. Together, these data suggest that artemisinin may be a useful agent to treat humans with cancer and could also be relevant to the treatment of dogs with cancer.
Given the low toxicity for artemisinin and the antineoplastic activity of artemisinin in humans with cancer and human cell lines, as well as anecdotal reports of efficacy in dogs with cancer (especially osteosarcoma), an increasing number of pet owners are treating their cancer-affected dogs with artemisinin, which is readily accessible as an over-the-counter product. To our knowledge, no studies investigating the potential antineoplastic effects of artemisinin in canine cancer cells have been published. Therefore, the study reported here was initiated to evaluate the in vitro effects of dihydroartemisinin, the active metabolite of most artemisinin derivatives, on cell viability, cytotoxicosis, and cell cycle progression in canine osteosarcoma cell lines.
Materials and Methods
Sample population-Four canine osteosarcoma cell lines (D17, a OSCA2, b OSCA16, b and OSCA50 b ) were evaluated. The D17 cell line was established from an osteosarcoma that had metastasized to the lungs of an 11-year-old female Standard Poodle. The OSCA cell lines were established from primary osteoblastic osteosarcomas (OSCA-2 was from a 2-year-old male Rottweiler, OSCA-16 was from a 10-year-old Rottweiler, and OSCA-50 was from a 7.5-year-old Saint Bernard).
Cell culture-Cells of the D17 cell line were cultured in RPMI-1640 c supplemented with 10% fetal bovine serum d and antimicrobials (penicillin [100 U/mL] and streptomycin [0.1 mg/mL]).
e The OSCA cell lines were cultured in Dulbecco modified Eagle medium c supplemented with 10% fetal bovine serum and antimicrobials (penicillin [100 U/mL] and streptomycin [0.1 mg/mL]). All cell lines were maintained in a humidified environment of 95% room air and 5% carbon dioxide at 37°C. The doubling times of these cell lines for these culture conditions were approximately 24 hours for D17, OSCA-2, and OSCA-50 and 36 hours for OSCA-16.
Dihydroartemisinin-Dihydroartemisinin
f was dissolved in 100% DMSO at a concentration of 100mM to create a stock solution, which was then protected from light and kept in long-term storage at -80°C. The stock solution was further diluted with DMSO prior to use in tissue culture, which resulted in a consistent DMSO concentration of 0.1% volume per condition. Dihydroartemisinin solutions were newly prepared from the stock solution for each experiment.
Assessment of cell viability-Cells were seeded in 96-well plates at densities of 1,000 to 2,000 cells/well (final volume, 100 µL/well) in 6 replicates. After 24 hours, 100 µL of medium containing DMSO (control wells) or various concentrations of dihydroartemisinin was added to each well to create final dihydroartemisinin concentrations of 0.1, 1, 5, 10, 50, and 100µM, and the cells were incubated for an additional 48 hours. After that incubation, medium was removed by gentle suction, and plates were stored at -80°C until use. Cell proliferation was assessed by use of a nucleic acid fluorescence assay kit, g which was conducted in accordance with the manufacturer' s instructions. After subtraction of background values, intensity of fluorescence of each reaction product was measured by use of a plate reader h with excitation at 485 nm and emission detection at 530 nm. Cell proliferation was expressed as a percentage of the control wells by use of the following equation: (fluorescence of sample wells/fluorescence of control wells) X 100. Experiments were repeated a minimum of 3 times.
Assessment of nucleosome fragmentation (cell death)-To assess drug-induced apoptotic cell death, an ELISA kit i was used in accordance with the manufacturer' s instructions. The ELISA was based on the quantitative determination of cytoplasmic histone-associated DNA fragments in the form of mononucleosomes or oligonucleosomes generated after apoptotic cell death. Briefly, 2.0 to 5.0 X 10 5 osteosarcoma cells were cultured in medium in 6-well plates for 24 hours before treatment. Cells were incubated with various concentrations of dihydroartemisinin (0 to 40µM) or DMSO (control wells) for 24 hours. Then cells were collected, and 1.0 X 10 5 cells were counted and used in the ELISA.
Western immunoblot analysis-Osteosarcoma cell lines were incubated with various concentrations of dihydroartemisinin or DMSO (control wells) and collected after 24 hours of exposure. Cells were lysed in protein extraction reagent, j unless otherwise stated. Additionally, a protease inhibitor cocktail mixture k and phosphatase inhibitors l,m were added to the lysis buffer. Cells were washed with ice-cold PBS solution and resuspended in lysis buffer containing 20mM Tris-HCl (pH, 8.0), 137mM NaCl, 1mM CaCl 2 , 10% glycerol, 1% nonionic detergent, n 0.5% deoxycholate, 0.1% SDS, 100µM 4-(2-aminoethyl)-benzenesulfonyl fluoride, leupeptin at 10 µg/mL, and aprotinin at 10 µg/mL. After protein quantitation, equivalent amounts of proteins (50 to 100 µg) from each lysate were resolved on 8% SDS-polyacrylamide gels o and transferred to nitrocellulose membranes.
p Membranes were washed with TBST, blocked by incubation in 5% skim milk in TBST for 1 hour at 20°C, and probed with antibodies specific for caspase 3 q or β-actin r (both at a dilution of 1:500 in TBST and 5% bovine serum albumin) by incubation overnight at 4°C. Membranes were then washed and incubated with goat anti-rabbit IgG conjugated to horseradish peroxidase s (dilution of 1:15,000) in 2.5% milk in TBST for 1 hour. Blots were then developed by use of a labeling reagent. Cell-cycle analysis-For detection of cell-cycle progression and cell death, cell lines were seeded in 6-well plates at a density of 2.0 X 10 5 cells/well. Cells were incubated for 24 hours, after which the medium was replaced with medium containing DMSO (control wells) or 1, 10, or 50µM dihydroartemisinin. Plates were then incubated for 24, 48, or 72 hours, after which cells were collected, washed with PBS solution, and fixed in 70% ethanol. Cell suspensions were stored overnight at 4°C. Fixed cells were washed in 5 mL of PBS solution and suspended in 500 µL of PBS solution containing RNase A (100 µg/mL) and propidium iodide u (50 µg/mL). Flow cytometric analysis v was performed. Data were analyzed by use of commercially available software.
w Accumulation of cells in the sub G 0 /G 1 phase of the cell cylcle, an indicator of DNA fragmentation and apoptosis, was used to quantify cell death. Experiments were repeated 2 times. 
Measurement of ROS-Production

Results
Dihydroartemisinin decreased cell viability in all 4 canine osteosarcoma cell lines in a dose-dependent manner (Figure 1) . A significant decrease in cell viability was detected at concentrations of 5, 50, 10, and ≥ 10µM for D17, OSCA2, OSCA16, and OSCA50 cell lines, respectively. Calculated IC 50 values for the cell lines were 8.7, 43.6, 16.8, and 14.8µM for D17, OSCA2, OSCA16, and OSCA50, respectively. Microscopic examination revealed cellular fragmentation and loss of attachment to the cell culture plate in all 4 cell lines (data not shown). In contrast, DMSO-treated (control) cells had no evidence of cytotoxicosis.
The mode of dihydroartemisinin-induced cell death was assessed by use of an ELISA-based technique for detection and quantitative determination of cytoplasmic histone-associated DNA fragments in the form of mononucleosomes or oligonucleosomes. Histone-associated DNA fragments are generated during the process of apoptosis and thus represent a quantitative measure of this process. Dihydroartemisinin treatment induced a dose-dependent increase in formation of free cytoplasmic nucleosomes (Figure 2) . A significant increase in cytoplasmic nucleosomes was detected at a concentration of 10µM for the D17, OSCA16, and OSCA50 cell lines and at a concentration of 40µM for the OSCA2 cell line. This was accompanied by cleavage of caspase 3 (Figure 3) . Considered together, these data indicated that the antiproliferative effect of dihydroartemisinin was attributable, at least in part, to apoptosis of treated cells.
Effects of dihydroartemisinin on cell-cycle progression were evaluated. An increase in the proportion of cells in the sub G 0 /G 1 phase was detected in all 4 cell lines after incubation with dihydroartemisinin, which suggested induction of apoptosis (Figure 4 ; Table 1 ). Dihydroartemisinin treatment also resulted in an increase in the proportion of G 2 /M phase populations and a decrease in the proportion of G 0 /G 1 phase populations for all 4 cell lines.
Finally, to determine whether dihydroartemisinin cytotoxic effects in canine osteosarcoma cells reflected a hypothesized iron-mediated generation of ROS, induction of ROS was measured in the D17 cell line. The 6-carboxy-2',7'-dichlorodihydrofluorescein is a cell-permeating nonfluorescent probe that fluoresces after oxidation by ROS, which can be measured by use of flow cytometric analysis. Thus, an increase in fluorescence indicated an increase in the amount of ROS. Dihydroartemisinin induced a dose-dependent increase in generation of ROS in D17 cells ( Figure 5 ). This increase in ROS Results were similar when the experiment was repeated 2 additional times. *A significant (P = 0.01) decrease in cell viability was detected at concentrations of ≥ 5µM (D17), 10µM (OSCA16 and OSCA50), and 50µM (OSCA2) dihydroartemisinin, compared with values for 0µM dihydroartemisinin. was significantly suppressed by prior incubation of cells with the iron chelator desferrioxamine, which is consistent with results of other studies regarding the role of iron in cytotoxic effects of artemisinin. Hydrogen peroxide, an established inducer of ROS, also was able to induce generation of ROS in D17 cells in vitro.
Discussion
During the past 2 decades, the antimalarial agent artemisinin and its derivatives have attracted substantial interest as potential novel anticancer agents, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] cancer preventatives, 25, 26 multidrug-resistance-reversal agents, 27, 28 and radiosensitizers. 29 Artemisinin-derived Values reported are percentages. In all 4 cell lines, there was a significant (P = 0.01) decrease of the G 0 /G 1 phase population and a significant increase in the sub G 0 /G 1 and G 2 /M phase populations. A repeat of the experiment yielded similar results. Table 1 -Distribution of the cell-cycle phase after incubation of 4 canine osteosarcoma cell lines with 10µM dihydroartemisinin or DMSO (control treatment) for 48 hours.
1,2,4-trioxanes have substantial activity at concentrations in the nanomolar to micromolar range against a number of human cancer cell lines. [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] [19] [20] The biological activity in human cancer cell lines and apparently low toxicity for human malaria patients have stimulated the use of artemisinin by owners for the treatment of dogs with various malignancies (particularly osteosarcomas) because the drug is readily available as an overthe-counter product. However, no investigators have conducted a study to critically evaluate the potential in vitro or in vivo activity of artemisinin against canine cancer cells.
In the study reported here, a dose-dependent decrease in the viability of osteosarcoma cell lines was detected after exposure to dihydroartemisinin. The IC 50 values for these cell lines ranged from 8.7 to 43.6µM. These values are similar to those reported 17 for exposure of the National Cancer Institute 55 human cancer cell line panel to 3 artemisinin derivatives (ie, artesunate, artemether, and arteether). For that panel, the greatest susceptibility was detected in leukemia and colon cancer cell lines (mean IC 50 , 1 to 2µM artesunate), and the lowest susceptibility was detected in non-small-cell lung cancer cell lines (mean IC 50 , 26µM artesunate). 17 Unfortunately, no sarcoma cell lines were tested.
In our study, we also detected a dose-dependent increase in cytoplasmic nucleosomes and accumulation of cleaved caspase 3, which is consistent with dihydroartemisinin-induced apoptotic cell death. Furthermore, there was a dose-dependent increase in the sub G 0 /G 1 phase population in treated cells, which provided additional support that the mechanism of cell death for dihydroartemisinin is attributable, at least in part, to apoptosis. Induction of apoptosis by artemisinin derivatives has been reported in other studies 6, 10, 15 in which investigators evaluated human cancer cell lines. A decrease in the proportion of cells in the G 0 /G 1 phase was evident in the cell-cycle analysis of dihydroartemisinin-treated cells. The underlying mechanism for this alteration in cell-cycle phase distributionis unknown.
One of the postulated mechanisms of artemisinin-and dihydroartemisinin-induced cytotoxicosis is iron-mediated generation of ROS, which is evident for antimalarial activity. Both antimalarial and tumoricidal activities of artemisinin are iron-dependent events. 26, 30 For example, the in vitro cytotoxic effects of dihydroartemisinin in papilloma virus-infected epithelial cells can be reversed by chelating iron from the culture medium. 26 To confirm that there was generation of ROS in canine osteosarcoma cells, we measured ROS activity in the D17 cell line after incubation with dihydroartemisinin. As expected, the generation of ROS by dihydroartemisinin was evident in a dose-dependent manner. Generation of ROS was completely inhibited by addition of desferroxamine (an iron-chelating agent) to the culture medium, which indicated that generation of ROS by dihydroartemisinin also is an iron-dependent event in canine cells.
The intrinsic oxidative stress of cancer cells is a feature that can be exploited therapeutically. In addition to artemisinin and its derivatives, a number of commonly used chemotherapeutic agents, including procarbazine, anthracyclines, cisplatin, bleomycin, and ionizing radiation, exert at least a portion of their killing effect on cancer cells through the production of free radicals. 31, 32 Because cancer cells generate large amounts of ROS and are more dependent on antioxidant enzymes than are normal cells, it would suggest that inhibition of antioxidant enzymes or exposure to additional amounts of exogenous ROS may offer a unique therapeutic opportunity. Other compounds that increase generation of ROS that are being investigated include arsenic trioxide, emodin, bortezomib, histone deacetylase inhibitors, and N-(4-hydroxyphenyl) retinamide. 32, 33 Analysis of the data for the study reported here indicated that dihydroartemisinin-induced apoptosis of canine osteosarcoma cell lines required drug concentra- , which were then treated with 5µM 6-carboxy-2',7'-dihydrofluorescein diacetate to evaluate generation of ROS. In panel A, a dosedependent increase in production of ROS in response to dihydroartemisinin is indicated by the shift of the curves to the right. In panel B, a reduction in the shift of the curves for all concentrations of dihydroartemisinin indicated that the formation of ROS in response to dihydroartemisinin treatment is an iron-dependent event. In panel C, D17 cells were incubated for 2 hours with 0.1% DMSO (black line), 500µM hydrogen peroxide (purple line), and a combination of 500µM hydrogen peroxide and 0.1% DMSO (gray line), which was followed by treatment with 5µM 6-carboxy-2',7'-dihydrofluorescein diacetate. Hydrogen peroxide induced ROS production as indicated by the shift of the curve to the right, compared with incubation with 0.1% DMSO, which did not affect ROS production.
tions in the micromolar range. Peak plasma concentrations after an antimalarial dose of orally administered dihydroartemisinin (4 mg/kg) in human malaria patients range from 1.9 to 16µM (median, 4µM). 34 These values are lower than the cytotoxic range for our study; however, the low amount of toxic effects for artemisinins in human patients and the extremely high LD 50 values of artemisinin derivatives in another study 35 in rats and mice suggest that cytotoxic plasma concentrations could be achievable in vivo by use of higher doses of artemisinin derivatives than those currently being empirically used in dogs.
Analysis of our data indicated in vitro biological activity of dihydroartemisinin against multiple canine osteosarcoma cell lines. Additional studies are warranted to evaluate the in vivo safety and efficacy of artemisinin and its derivatives in dogs with osteosarcoma. Desferrioxamine mesylate, Hospira, Lake Forest, Ill. z.
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